Are you someone or do you know someone who lives with severe asthma and are hoping to potentially reduce or end the need for oral corticosteroids (OCS)? We invite eligible individuals to explore the possibilities through the SUNRISE clinical research study.
SUNRISE is a clinical research study that aims to investigate whether tezepelumab may help to reduce or remove the need for OCS in adults with severe asthma.
Many individuals with corticosteroid-dependent asthma rely on daily OCS along with other treatments (such as inhalers) to help control their asthma. However, long-term use of OCS may lead to unwanted side effects.
Click here to learn more and check your eligibility
Eligibility requirements
- Are between 18 and 80 years of age
- Have had an asthma diagnosis for at least 1 year
- Have been taking OCS for asthma for at least 6 months
- Have been using inhaled corticosteroids for at least 1 year, and a long-acting beta 2-agonist (LABA) for at least 3 months
- Have not been receiving any biologic treatment for asthma for at least 4 months
If you are eligible to take part, what can you expect as a participant?
- Will receive expert medical care, related to the study, at no cost to participant
- May receive compensation, relating to time and travel costs
- Will help to make a difference for people using chronic OCS for uncontrollable asthma in the future
During this study, the participant may receive an experimental treatment aimed at reducing OCS usage. As individuals may experience exacerbations by reducing their OCS and inhaled corticosteroids (ICS) medications, your health and safety will be monitored by the study physician.
To learn more about the SUNRISE study and determine if you qualify, please visit our website.
If you have any questions or need further assistance, don’t hesitate to call our dedicated phone line at 866-914-6996.
Sponsored by AstraZeneca
810304 Eaton Place, Suite 100
